Commonly reported side effects of darunavir include: skin rash. Other side effects include: nausea.  See below for a comprehensive list of adverse effects.
Applies to darunavir: oral suspension, oral tablet
In addition to its needed effects, some unwanted effects may be caused by darunavir. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking darunavir:
Some of the side effects that can occur with darunavir may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to darunavir: oral suspension, oral tablet
Most side effects reported during therapy with darunavir/ritonavir were mild in severity.  The most common side effects were diarrhea, nausea, vomiting, headache, rash, and abdominal pain.  Adverse events led to therapy discontinuation in 2.3% and 4.7% of therapy-naive and therapy-experienced subjects, respectively, in randomized trials.The most common side effects reported with darunavir/cobicistat were diarrhea, nausea, and rash.  The manufacturer product information for cobicistat should be consulted.[Ref]
Elevated pancreatic amylase (Grade 2: up to 7.4%; Grade 3: up to 7.8%; Grade 4: up to 1.1%) and pancreatic lipase (Grade 2: 5.2%; Grade 3: up to 2.6%; Grade 4: less than 1%) have been reported with darunavir/ritonavir.[Ref]
Darunavir/ritonavir:-Very common (10% or more): Diarrhea (up to 14.4%)-Common (1% to 10%): Nausea, vomiting, abdominal pain, elevated pancreatic amylase, elevated pancreatic lipase, abdominal distension, dyspepsia, flatulence, elevated blood amylase-Uncommon (0.1% to 1%): Pancreatitis, acute pancreatitis, gastritis, gastroesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, elevated lipase, eructation, oral dysesthesia-Rare (less than 0.1%): Stomatitis, hematemesis, cheilitis, dry lip, coated tongue-Frequency not reported: Elevated pancreatic enzymeDarunavir/cobicistat:-Very common (10% or more): Diarrhea (28%), nausea (23%)-Common (1% to 10%): Vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, increased pancreatic enzymes-Uncommon (0.1% to 1%): Acute pancreatitis[Ref]
Darunavir/ritonavir:-Very common (10% or more): Elevated total cholesterol (up to 25%), elevated glucose levels (up to 15.4%), elevated low-density lipoprotein cholesterol (up to 14.4%), elevated triglycerides (up to 10.4%)-Common (1% to 10%): Hyperlipidemia, anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia-Uncommon (0.1% to 1%): Gout, decreased appetite, polydipsia, decreased weight, increased weight, hyperglycemia, insulin resistance, decreased high density lipoprotein, increased appetite, elevated LDH-Frequency not reported: Hypoglycemia, hyperuricemia, decreased bicarbonate, hypocalcemia, hyponatremia, hypernatremia, obesity, hypoalbuminemia-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, ketoacidosis, redistribution of body fatDarunavir/cobicistat:-Common (1% to 10%): Anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperlipidemiaCombination antiretroviral therapy:-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), metabolic abnormalities (such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia)HIV protease inhibitor therapy:-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes, hyperglycemia, diabetic ketoacidosis[Ref]
Elevated total cholesterol (Grade 2: up to 25%; Grade 3: up to 10%), glucose levels (Grade 2: up to 15.4%; Grade 3: up to 1.7%; Grade 4: less than 1%), low-density lipoprotein cholesterol (Grade 2: 14.4%; Grade 3: up to 9.1%), and triglycerides (Grade 2: up to 10.4%; Grade 3: up to 8.2%; Grade 4: up to 3.9%) have been reported with darunavir/ritonavir.[Ref]
Darunavir/ritonavir:-Common (1% to 10%): Rash (including macular, maculopapular, papular, erythematous, pruritic rash), pruritus, lipodystrophy (including lipohypertrophy, lipodystrophy, lipoatrophy)-Uncommon (0.1% to 1%): Angioedema, generalized rash, urticaria, night sweats, allergic dermatitis, eczema, erythema, alopecia, hyperhidrosis, Stevens-Johnson syndrome, acne, dry skin, nail pigmentation, herpes simplex-Rare (less than 0.1%): Drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, dermatitis, seborrheic dermatitis, skin lesion, xeroderma-Frequency not reported: Folliculitis, lipoatrophy, toxic skin eruption, dermatitis medicamentosa, skin inflammation, severe skin reactions (in some cases accompanied by fever and/or elevations of transaminases)-Postmarketing reports: Toxic epidermal necrolysis, acute generalized exanthematous pustulosis, DRESSDarunavir/cobicistat:-Very common (10% or more): Rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalized rash, allergic dermatitis; 16%)-Common (1% to 10%): Angioedema, pruritus, urticaria[Ref]
Darunavir/ritonavir:-Common (1% to 10%): Headache, peripheral neuropathy, dizziness-Uncommon (0.1% to 1%): Lethargy, hypoesthesia, paresthesia, dysgeusia, disturbance in attention, memory impairment, somnolence, vertigo-Rare (less than 0.1%): Syncope, convulsion, ageusia, sleep phase rhythm disturbance-Frequency not reported: Transient ischemic attack, progressive multifocal leukoencephalopathyDarunavir/cobicistat:-Very common (10% or more): Headache[Ref]
Darunavir/ritonavir:-Common (1% to 10%): Elevated ALT, elevated AST-Uncommon (0.1% to 1%): Hepatitis, acute hepatitis, cytolytic hepatitis, hepatic steatosis, hepatotoxicity, elevated transaminase, elevated blood bilirubin/hyperbilirubinemia, elevated blood alkaline phosphatase, elevated GGT-Frequency not reported: Elevated hepatic enzymeDarunavir/cobicistat:-Common (1% to 10%): Increased hepatic enzyme[Ref]
Hyperbilirubinemia (Grade 2: less than 1%; Grade 3: less than 1%; Grade 4: less than 1%), and elevated ALT (Grade 2: up to 9%; Grade 3: up to 3%; Grade 4: up to 1%), AST (Grade 2: up to 7%; Grade 3: up to 4.1%; Grade 4: up to 1.2%), and alkaline phosphatase (Grade 2: up to 3.9%; Grade 3: less than 1%) have been reported with darunavir/ritonavir.In patients receiving darunavir/ritonavir, the incidence of side effects and clinical chemistry abnormalities was not higher in those coinfected with hepatitis B or C virus compared with patients who were not coinfected, with the exception of elevated hepatic enzymes.[Ref]
Darunavir/ritonavir:-Common (1% to 10%): Insomnia-Uncommon (0.1% to 1%): Depression, disorientation, sleep disorder, abnormal dreams, nightmare, anxiety, decreased libido, irritability-Rare (less than 0.1%): Confusion state, altered mood, restlessnessDarunavir/cobicistat:-Common (1% to 10%): Abnormal dreams[Ref]
Darunavir/ritonavir:-Common (1% to 10%): Asthenia, fatigue-Uncommon (0.1% to 1%): Pyrexia, chest pain, peripheral edema, flushing, malaise, feeling hot, pain-Rare (less than 0.1%): Chills, abnormal feeling, xerosis-Frequency not reported: Rigors, hyperthermiaDarunavir/cobicistat:-Common (1% to 10%): Fatigue-Uncommon (0.1% to 1%): Asthenia[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Myocardial infarction, angina pectoris, prolonged ECG QT, tachycardia, hypertension-Rare (less than 0.1%): Acute myocardial infarction, sinus bradycardia, palpitations[Ref]
Spontaneous bleeding in patients with hemophilia A and B has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Thrombocytopenia, neutropenia, anemia, leukopenia-Rare (less than 0.1%): Elevated eosinophil count-Frequency not reported: Decreased white blood cell count, decreased lymphocytes, decreased total absolute neutrophil count, decreased platelets, increased partial thromboplastin time, increased plasma prothrombin timeHIV protease inhibitor therapy:-Frequency not reported: Increased/spontaneous bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Acute renal failure, renal failure, nephrolithiasis, elevated blood creatinine-Rare (less than 0.1%): Decreased creatinine renal clearance-Frequency not reported: Renal insufficiencyDarunavir/cobicistat:-Common (1% to 10%): Increased blood creatinine[Ref]
Osteonecrosis has been reported, particularly with commonly known risk factors (e.g., corticosteroid use, alcohol use, severe immunosuppression, higher body mass index), advanced HIV disease, or long-term combination antiretroviral therapy.Increased CPK, myalgia, myositis, and rarely, rhabdomyolysis have been reported with HIV protease inhibitors, especially when coadministered with nucleoside reverse transcriptase inhibitors.[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremities, osteoporosis, elevated blood creatine phosphokinase (CPK)-Rare (less than 0.1%): Musculoskeletal stiffness, arthritis, joint stiffness-Frequency not reported: Osteopenia-Postmarketing reports: RhabdomyolysisDarunavir/cobicistat:-Common (1% to 10%): MyalgiaHIV protease inhibitor therapy:-Frequency not reported: Increased CPK, myalgia, myositis, rhabdomyolysis[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Dyspnea, cough, epistaxis, throat irritation-Rare (less than 0.1%): Rhinorrhea-Frequency not reported: Nasopharyngitis, hiccups, pneumonia, upper respiratory tract infection[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Drug hypersensitivity-Frequency not reported: Facial edemaDarunavir/cobicistat:-Common (1% to 10%): Drug hypersensitivity[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria, erectile dysfunction-Frequency not reported: Polyuria[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Immune reconstitution syndromeDarunavir/cobicistat:-Uncommon (0.1% to 1%): Immune reconstitution inflammatory syndromeCombination antiretroviral therapy:-Frequency not reported: Immune reconstitution inflammatory syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Hypothyroidism, elevated blood thyroid stimulating hormone, gynecomastia[Ref]
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Conjunctival hyperemia, dry eye-Rare (less than 0.1%): Visual disturbance[Ref]
1. HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2014 Feb 12]):
2. Fenton C,  Perry CM "Darunavir: In the Treatment of HIV-1 Infection." Drugs 67 (2007): 2791-801
3. Rittweger M,  Arasteh K "Clinical pharmacokinetics of darunavir." Clin Pharmacokinet 46 (2007): 739-56
4. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22
5. Taiwo BO,  Hicks CB "Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance." AIDS Read 17 (2007): 151-6, 159-61
6. "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ. 
7. McCoy C "Darunavir: a nonpeptidic antiretroviral protease inhibitor." Clin Ther 29 (2007): 1559-1576
8. Cerner Multum,  Inc. "Australian Product Information." O 0
9. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
10. Hoffman CJ,  Gallant JE "When and how to use tipranavir and darunavir." AIDS Read 17 (2007): 194-8, 201
11. Clotet B,  Bellos N,  Molina JM, et al. "Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials." Lancet 369 (2007): 1169-78
12. Busse KH,  Penzak SR "Darunavir: A second-generation protease inhibitor." Am J Health Syst Pharm 64 (2007): 1593-602
13. Holodniy M "Darunavir in the Treatment of HIV-1 Infection: A Viewpoint by Mark Holodniy." Drugs 67 (2007): 2802-3
14. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9
15. "Darunavir (Prezista) for HIV infection." Med Lett Drugs Ther 48 (2006): 74-5
16. Katlama C,  Esposito R,  Gatell JM, et al. "Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1." AIDS 21 (2007): 395-402
17. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2013 Feb 12]):
18. Sekar V,  Kestens D,  Spinosa-Guzman S, et al. "The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers." J Clin Pharmacol 47 (2007): 479-84
19. Hammer SM,  Saag MS,  Schechter M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA 296 (2006): 827-43
20. Poveda E,  Blanco F,  Garcia-Gasco P,  Alcolea A,  Briz V,  Soriano V "Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors." AIDS 20 (2006): 1558-60
21. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88
Not all side effects for darunavir may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Blurred vision
dry mouth
flushed, dry skin
fruit-like breath odor
increased hunger
increased thirst
increased urination
skin rash
sweating
troubled breathing
unexplained weight loss
unusual tiredness or weakness


Abdominal or stomach pain or tenderness
acid or sour stomach
belching
blistering, peeling, or loosening of the skin
bloating
chills
clay colored stools
constipation
cough
dark urine
decreased appetite
diarrhea
difficulty with moving
dizziness
excess air or gas in the stomach or intestines
fast heartbeat
fever
full feeling
headache
heartburn
indigestion
itching
joint or muscle pain
lack or loss of strength
light-colored stools
loss of appetite
muscle aching or cramping
nausea and vomiting
passing gas
red skin lesions, often with a purple center
red, irritated eyes
sore throat
sores, ulcers, or white spots in the mouth or on the lips
swelling of the feet or lower legs
swollen joints
unpleasant breath odor
vomiting of blood
yellow eyes or skin


Muscle pain or stiffness
swelling or puffiness of the face


Stuffy or runny nose


Gaining weight around your neck, upper back, breast, face, or waist

